Try our beta test site

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

This study has been completed.
Information provided by (Responsible Party):
Retinal Consultants of Arizona Identifier:
First received: August 22, 2012
Last updated: April 1, 2015
Last verified: March 2014
There is a need to find an effective therapy for diabetic patients who develop macular edema after cataract surgery. The objective of this study is to assess the safety and efficacy of the OZURDEX® intraocular implant in patients with diabetes mellitus, who develop macular edema after cataract surgery.

Condition Intervention Phase
Macular Edema After Cataract Surgery in Patients With Diabetes Mellitus
Drug: Dexamethasone intravitreal implant
Drug: Steroid plus NSAID eye drop combination therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Retinal Consultants of Arizona:

Primary Outcome Measures:
  • Percentage of patients with significant decrease in OCT (e.g., 50-100 µm) following treatment with OZURDEX®. [ Time Frame: 3 months ]

Enrollment: 40
Study Start Date: November 2012
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OZURDEX intraocular implant
OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
Drug: Dexamethasone intravitreal implant
Other Name: OZURDEX
Active Comparator: Steroid plus NSAID eye drop combination therapy
NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
Drug: Steroid plus NSAID eye drop combination therapy
Other Name: Acular LS and Pred Forte


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has diagnosis of Diabetes Mellitus, Type I or II.
  • Patient has experienced the development of macular edema following cataract surgery in at least one eye.
  • Patient has had cataract surgery within 90 days prior to the screening visit.

Exclusion Criteria:

  • Patient has other significant ocular disease in study eye, including glaucoma.
  • Patient has any active infection in the study eye.
  • Patient has uncontrolled systemic illness (i.e., uncontrolled blood pressure, uncontrolled diabetes mellitus).
  • Patient has experienced a significant increase in intraocular pressure following a prior treatment with topical or intravitreal steroidal medication.
  • Patient has received the OZURDEX® implant before in the study eye.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01673191

United States, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85014
Sponsors and Collaborators
Retinal Consultants of Arizona
Principal Investigator: Pravin U Dugel, MD Retinal Consultants of Arizona
  More Information

Responsible Party: Retinal Consultants of Arizona Identifier: NCT01673191     History of Changes
Other Study ID Numbers: RCA2012
Study First Received: August 22, 2012
Last Updated: April 1, 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Macular Edema
Capsule Opacification
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lens Diseases
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Dexamethasone acetate
Prednisolone acetate
Dexamethasone 21-phosphate
BB 1101
Ophthalmic Solutions
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on March 28, 2017